Search clinical trials for: Secukinumab (150 mg)

Total 16605 results

AstraZeneca

Completed

AZD5069 Neutrophil Function Study

Chemokine Receptor 2 (CXCR2) Antagonist

United Kingdom
Vertex Pharmaceuticals Incorporated
Cystic Fibrosis Foundation

Completed

Safety Study of Ivacaftor in Subjects With Cystic Fibrosis

Cystic Fibrosis

United States, Canada, Germany
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate...

Completed

Bioequivalence of 5 Tablets of 100 mg Versus 2 Tablets of 250 mg TF3 of Tepotinib

Healthy

Germany
Novartis Pharmaceuticals

Completed

Aliskiren in Combination With Losartan Compared to Losartan on the Regression of Left Ventricular Hypertrophy in Overweight Patients With Essential Hypertension (ALLAY)

Hypertension | Overweight | Left Ventricular Hypertrophy

United States, Finland, Sweden, Germany, Italy, Spain, Argentina, Colombia, Russian Federation
Novartis Pharmaceuticals

Completed

A Prospective Multicenter Study for the Assessment of Treatment Patterns, Effectiveness and Safety of Secukinumab in Adult Patients With Moderate to Severe Plaque Psoriasis in a Real-world Setting in China (UNMASK2)

Psoriasis

China
Novartis Pharmaceuticals

Terminated

Study of Safety, Efficacy and Tolerability of Secukinumab Versus Placebo, in Combination With SoC Therapy, in Patients With Active Lupus Nephritis (SELUNE)

Lupus Nephritis

China, Croatia, Czechia, Russian Federation, Turkey, Australia, Spain, Thailand, Argentina, United States, Denmark, Greece, Romania, Germany, Korea, Republic of, India, Brazil, Japan, Peru, Portugal, Italy, Taiwan, Vietnam, Norway, Colo... and more
Novartis Pharmaceuticals

Completed

An Analysis of the Improvement and Quality of Life Trends for UK/ROI Patients Treated With Cosentyx (Secukinumab) in a Retrospective Analysis of the BADBIR Data Source

Plaque Psoriasis

United States
Mayo Clinic

Completed

Cosentyx (Secukinumab) for the Treatment of Adult Onset Pityriasis Rubra Pilaris

PITYRIASIS RUBRA PILARIS

United States
Narrows Institute for Biomedical Research
Novartis

Unknown

Secukinumab Therapy for the Treatment of Moderate to Severe Plaque Psoriasis With Response Monitoring Using Optical Coherence Tomography (OCT).

Psoriasis Vulgaris

United States
Icahn School of Medicine at Mount Sinai
Novartis

Completed

Secukinumab for Treatment of Atopic Dermatitis

Atopic Dermatitis

United States
Tufts Medical Center

Completed

Exploratory Trial Evaluating Cosentyx (Secukinumab) for Patients With Moderate-to-Severe Hidradenitis Suppurativa

Hidradenitis Suppurativa

United States
Novartis Pharmaceuticals

Completed

Secukinumab in Tumor Necrosis Factor (TNF) - Inadequate Response (IR) Psoriasis Participants. (SIGNATURE)

Psoriasis

United Kingdom, Ireland
Johns Hopkins All Children's Hospital

Terminated

Study of Lenalidomide With Vorinostat in Pediatric Patients With High Grade or Progressive CNS Tumors

Central Nervous System Tumors

United States
Corcept Therapeutics

Active, not recruiting

Dazucorilant in Patients With Amyotrophic Lateral Sclerosis (DAZALS)

Amyotrophic Lateral Sclerosis

United States, Belgium, Canada, France, Germany, Ireland, Netherlands, Poland, Spain, United Kingdom
RemeGen Co., Ltd.

Recruiting

A Study of Telitacicept in Lupus Nephritis

Lupus Nephritis

China
Celgene

Completed

Safety and Pharmacokinetics of AVL-292 Following Multiple Doses and the Effect of Food on the Single-dose Pharmacokinetics of AVL-292

Healthy

United States
Revogenex, Inc.

Suspended

A Four Arm Study to Evaluate the Safety and Efficacy of 3 Different Doses of RVX-100 Versus Placebo in Subjects With Irritable Bowel Syndrome Accompanied by Diarrhea (IBS-D)

Irritable Bowel Syndrome

United States
Empros Pharma AB
CTC Clinical Trial Consultants AB

Completed

A Proof of Concept Trial in Overweight and Obese Patients, Investigating Effect of EMP16-02 on Body Weight (Primary)

Overweight or Obesity

Sweden
Sixth Affiliated Hospital, Sun Yat-sen University

Not yet recruiting

Prospective Clinical Study of Nintedanib to Inhibit Endometrial Fibrosis to Prevent Recurrence of Uterine Adhesions

Uterine Adhesions
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of Secukinumab in Chinese Subjects With Active PsA Compared to Placebo.

Psoriatic Arthritis

China
Novo Nordisk A/S

Completed

A Trial to Assess the Pharmacokinetics, Safety and Tolerability of Semaglutide in Healthy Chinese Subjects

Diabetes Mellitus, Type 2 | Diabetes

China
Novartis Pharmaceuticals

Not yet recruiting

Prospective Observational Study to Evaluate Secukinumab Treatment Effectiveness in Pediatric Patients With Active Juvenile Enthesitis-related or Psoriatic Arthritis (Toddler)

Juvenile Idiopathic Arthritis
Taizhou Mabtech Pharmaceutical Co.,Ltd

Completed

Pharmacokinetic, Safety and Immunogenicity Study of CMAB015 and Cosentyx in Healthy Volunteers

Psoriasis

China
Novartis Pharmaceuticals

Active, not recruiting

2 Years Prospective Study to Collect Real-life Data on the Retention, Quality of Life, Effectiveness and Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis (PROMPT)

Psoriatic Arthritis | Ankylosing Spondylitis | Moderate to Severe Plaque Psoriasis | Non-radiographic Axial Spondyloarthritis

Thailand
University Hospital, Ghent
Novartis

Completed

Secukinumab in Active Non-segmental Vitiligo

Vitiligo | Secukinumab

Belgium
University of Erlangen-Nürnberg Medical School

Completed

Psoriasis-Arthritis & Bone Program (PSARTROS)

Psoriasis | Psoriatic Arthritis

Germany
Novartis Pharmaceuticals

Completed

Secukinumab Dosage Optimisation in Partial Responders With Moderate to Severe Plaque-type Psoriasis (GAIN)

Moderate to Severe Plaque-type Psoriasis

Germany
Novartis Pharmaceuticals

Completed

Plaque Psoriasis Efficacy and Safety With Secukinumab (OPTIMISE)

Plaque Psoriasis

Germany, Belgium, Spain, Croatia, Czechia, Greece, Hungary, Russian Federation, Netherlands, Austria, France, Switzerland, Israel, United Kingdom, Italy, Lithuania, Sweden, Bulgaria, Denmark, Finland, Portugal, Slovakia, Poland, Latvia
Novartis Pharmaceuticals

Completed

Study to Assess the Efficacy, Safety and Tolerability of Secukinumab in Japanese Subjects With Generalized Pustular Psoriasis (GPP)

Psoriasis

Japan
Cerevance Beta, Inc.

Recruiting

Early Parkinson's Disease Monotherapy With CVN424

Parkinson's Disease

United States
Janssen R&D Ireland

Completed

A Study to Assess Bioavailability & Food Effect of Different Liquid and Capsule Formulations of TMC435.

Healthy Volunteers

United Kingdom
Innovation Pharmaceuticals, Inc.

Completed

Efficacy and Safety of Prurisol Administered Orally for Active Moderate to Severe Chronic Plaque Psoriasis

Chronic Stable Plaque Psoriasis

United States
Novartis Pharmaceuticals

Recruiting

Secukinumab Drug Survival, Effectiveness and Tolerability in Pediatric Patients With Psoriasis (SPARROW)

Moderate-to-severe Plaque Psoriasis

Russian Federation
Novartis Pharmaceuticals

Recruiting

Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Intravenous Secukinumab in Patients With GCA or PMR

Giant Cell Arteritis | Polymyalgia Rheumatica

United States, Spain, Switzerland, Portugal
Novartis Pharmaceuticals

Available

Secukinumab Global MAP Cohort for Adult Patients With Hidradenitis Suppurativa (HS)

Hidradenitis Suppurativa (HS)
University of California, San Francisco
Novartis Pharmaceuticals

Completed

Immunologic Response to Secukinumab in Plaque Psoriasis

Psoriasis

United States
Anne Chang

Completed

Open Label Study to Assess the Effect of Secukinumab in Moderate to Severe Papulopustular Rosacea

Papulopustular Rosacea

United States
Academisch Medisch Centrum - Universiteit van Amsterdam...
Novartis

Completed

Mechanism of Action of Anti-IL17 Therapy in Peripheral Spondyloarthritis (MoA aIL-17)

Spondylarthropathies

Netherlands
Memorial Sloan Kettering Cancer Center

Active, not recruiting

A Study of Olaparib and Low Dose Radiotherapy for Small Cell Lung Cancer

Small Cell Lung Carcinoma | Small-cell Lung Cancer

United States
Galapagos NV

Completed

A Study to Evaluate GLPG2222 in Ivacaftor-treated Subjects With Cystic Fibrosis

Cystic Fibrosis

Ireland, United Kingdom, Belgium, Australia, Czechia, Germany
City Clinical Hospital No.52 of Moscow Healthcare...
Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry...

Active, not recruiting

Study of Tixagevimab/Cilgavimab and Regdanvimab Efficacy for Treatment of COVID-19

Coronavirus Infections

Russian Federation
EMD Serono

Completed

Efficacy and Safety of Atacicept in Systemic Lupus Erythematosus (ADDRESS II)

Lupus Erythematosus, Systemic

Korea, Republic of, Philippines, Spain, United States, Czechia, Germany, United Kingdom, South Africa, Poland, Argentina, Italy, Chile, Bulgaria, Japan, Brazil, Mexico, Peru, Russian Federation
EMD Serono
Merck KGaA, Darmstadt, Germany

Completed

Atacicept Phase 2/3 in Generalized Systemic Lupus Erythematosus (APRIL-SLE) (APRIL-SLE)

Lupus Erythematosus, Systemic

United States, Croatia, Bulgaria, France, Korea, Republic of, Poland, Russian Federation, South Africa, Spain, United Kingdom, Germany, Malaysia, Latvia, Lithuania, Ukraine, Argentina, Israel, Netherlands, Greece, Taiwan, Philip... and more
Nocion Therapeutics

Completed

Placebo-controlled, Single and Multiple Dose Study in Healthy Volunteers and Refractory Chronic Cough Patients to Assess the Safety, Tolerability, and Pharmacokinetics of Two Formulations of NTX-1175

Refractory Chronic Cough

United States
National Institute of Allergy and Infectious Diseases...
AbbVie

Active, not recruiting

A Study to Evaluate the Effects of Cenicriviroc Mesylate on Arterial Inflammation in People Living With HIV

HIV-1-infection

United States
Luye Pharma Group Ltd.
Shandong Luye Pharmaceutical Co., Ltd.

Completed

Dose-Finding Clinical Trial to Evaluate the Efficacy and Safety of LY03005 Extended-release Tablets in the Treatment of Major Depressive Disorder (MDD)

Major Depressive Disorder

China
RemeGen Co., Ltd.

Recruiting

A Study to Evaluate the Efficacy and Safety of Telitacicept in Subjects With Active Primary Sjogren's Syndrome

Primary Sjogren's Syndrome

China
HighField Biopharmaceuticals Corporation
Tigermed Consulting Co., Ltd

Recruiting

Tolerability and Safety of HF1K16 Injection in Patients With Refractory Solid Tumors

Solid Tumor, Adult

China
Novartis Pharmaceuticals

Completed

Study to Demonstrate the Efficacy, Safety and Tolerability of an Intravenous Regimen of Secukinumab Compared to Placebo in Subjects With Active axSpA

Ankylosing Spondylitis

India, Turkey, Belgium, Thailand, United States, Czechia, Greece, Russian Federation, Bulgaria, Guatemala, Italy, Korea, Republic of, Malaysia, Sweden, Colombia, Philippines, Poland, Brazil
Novartis Pharmaceuticals

Terminated

A Study of the Efficacy and Safety of Secukinumab 300 mg in Patients With Thyroid Eye Disease (TED) (ORBIT)

Thyroid Eye Disease | Graves Orbitopathy

Germany

Search clinical trials for: Secukinumab (150 mg)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Armenia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations